| Year |
Citation |
Score |
| 2019 |
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal For Immunotherapy of Cancer. 7: 131. PMID 31113486 DOI: 10.1186/S40425-019-0602-4 |
0.304 |
|
| 2018 |
Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I, Wallden B, Marincola FM, Cesano A. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). Journal For Immunotherapy of Cancer. 6: 63. PMID 29929551 DOI: 10.1186/S40425-018-0367-1 |
0.326 |
|
| 2018 |
Turan T, Kannan D, Patel M, Matthew Barnes J, Tanlimco SG, Lu R, Halliwill K, Kongpachith S, Kline DE, Hendrickx W, Cesano A, Butterfield LH, Kaufman HL, Hudson TJ, Bedognetti D, et al. Immune oncology, immune responsiveness and the theory of everything. Journal For Immunotherapy of Cancer. 6: 50. PMID 29871670 DOI: 10.1186/S40425-018-0355-5 |
0.316 |
|
| 2018 |
Ho WS, Wang H, Maggio D, Kovach JS, Zhang Q, Song Q, Marincola FM, Heiss JD, Gilbert MR, Lu R, Zhuang Z. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. Nature Communications. 9: 2126. PMID 29844427 DOI: 10.1038/S41467-018-04425-Z |
0.397 |
|
| 2017 |
Ho WSC, Sizdahkhani S, Hao S, Song H, Seldomridge A, Tandle A, Maric D, Kramp T, Lu R, Heiss JD, Camphausen K, Gilbert MR, Zhuang Z, Park DM. LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation. Cancer Letters. PMID 29199006 DOI: 10.1016/J.Canlet.2017.11.035 |
0.309 |
|
| 2017 |
Ho WS, Wang H, Kovach JS, Lu R, Zhuang Z. Abstract LB-193: Protein phosphatase 2A inhibition,with a novel small molecule inhibitor, LB-100, achieves durable immune-mediated antitumor activity when combined with PD1 blockade in a preclinical model Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-193 |
0.361 |
|
| 2015 |
Rutz S, Kayagaki N, Phung QT, Eidenschenk C, Noubade R, Wang X, Lesch J, Lu R, Newton K, Huang OW, Cochran AG, Vasser M, Fauber BP, DeVoss J, Webster J, et al. Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cells. Nature. 518: 417-21. PMID 25470037 DOI: 10.1038/Nature13979 |
0.316 |
|
| 2013 |
Xin H, Lu R, Lee H, Zhang W, Zhang C, Deng J, Liu Y, Shen S, Wagner KU, Forman S, Jove R, Yu H. G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protein form a feed-forward loop in both normal and malignant myeloid cells. The Journal of Biological Chemistry. 288: 13842-9. PMID 23548897 DOI: 10.1074/Jbc.M113.450049 |
0.4 |
|
| 2012 |
Lu R, Pan H, Shively JE. CEACAM1 negatively regulates IL-1β production in LPS activated neutrophils by recruiting SHP-1 to a SYK-TLR4-CEACAM1 complex. Plos Pathogens. 8: e1002597. PMID 22496641 DOI: 10.1371/Journal.Ppat.1002597 |
0.441 |
|
| 2012 |
Lu R, Kujawski M, Pan H, Shively JE. Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. Cancer Research. 72: 2239-50. PMID 22406619 DOI: 10.1158/0008-5472.Can-11-3016 |
0.487 |
|
| 2011 |
Lu R, Niesen MJ, Hu W, Vaidehi N, Shively JE. Interaction of actin with carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) receptor in liposomes is Ca2+- and phospholipid-dependent. The Journal of Biological Chemistry. 286: 27528-36. PMID 21669871 DOI: 10.1074/Jbc.M111.235762 |
0.429 |
|
| 2011 |
Lu R, Shively J. Abstract 786: CEACAM1 regulates myeloid-cell-dependent tumor angiogenesis by inhibition of G-CSFR-Bv8 pathway Cancer Research. 71: 786-786. DOI: 10.1158/1538-7445.Am2011-786 |
0.366 |
|
| 2011 |
Lu R, Pan H, Shively J. PS2-017. Regulation of Syk mediated inflammasome activation in neutrophils by CEACAM1 by SHP-1recruitment Cytokine. 56: 67-68. DOI: 10.1016/J.Cyto.2011.07.177 |
0.445 |
|
| Show low-probability matches. |